Skyla
(levonorgestrel-releasing intrauterine system)

Full Safety and Drug Utilization Review Provided in Background Materials

Judith U. Cope, MD, MPH
Office of Pediatric Therapeutics
OC, FDA
Skyla – Pediatric Postmarket Review

- Skyla was first approved January 9, 2013 for use in adolescents and adults, which prompted this mandated pediatric postmarket review.
- Skyla is indicated for prevention of pregnancy for up to 3 years.
- Skyla is a small intrauterine system, T-shaped polyethylene frame with a steroid reservoir containing 13.5 mg levonorgestrel.
Pediatric Postmarket Safety and Use Review

16 unique cases with SAEs, no deaths, 4/4/2013 through 8/31/2015

✓ Types of SAEs (cases may include 1 or more SAEs)
  • 11 intrauterine system expulsion*
  • 4 altered bleeding (irregular spotting, frequent or heavy bleeding)
  • 2 pregnancy
  • 1 pelvic inflammatory disease

Of all users, the proportion who were pediatric patients aged 0-17 years with a prescription and/or procedure claim for Skyla was 6% (1,583 out of 26,915 total patients) from 8/2013 - 7/2015.**

* 1 expulsion had altered bleeding, 1 expulsion with pregnancy
**Data source: SHS Integrated Dataverse (IDV™), extracted Dec 2015 (Data obtained from a sample of 131 pharmacies, 3,258 clinics, hospitals and physician offices)
Skyla
(levonorgestrel-releasing intrauterine system)

FDA will continue its standard ongoing safety monitoring.

Does the Committee concur?